{"id": "hnyo1AUAAAAJ", "citedby": 8480, "citedby5y": 5192, "hindex": 36, "hindex5y": 32, "i10index": 65, "i10index5y": 59, "coauthors": [], "name": "Rita Nanda", "affiliation": "Associate Professor, The University of Chicago", "interests": ["breast cancer"], "cites_per_year": {"2006": 78, "2007": 180, "2008": 293, "2009": 358, "2010": 428, "2011": 413, "2012": 441, "2013": 486, "2014": 492, "2015": 585, "2016": 657, "2017": 923, "2018": 1129, "2019": 1241, "2020": 572}, "publications": [{"bib": {"title": "The molecular portraits of breast tumors are conserved across microarray platforms", "year": "2006"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:u5HHmVD_uO8C", "citedby": "1532"}, {"bib": {"title": "Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma", "year": "2006"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:u-x6o8ySG0sC", "citedby": "1286"}, {"bib": {"title": "Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study", "year": "2016"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:Tyk-4Ss8FVUC", "citedby": "678"}, {"bib": {"title": "Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer", "year": "2009"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:d1gkVwhDpl0C", "citedby": "383"}, {"bib": {"title": "Adaptive randomization of veliparib\u2013carboplatin treatment in breast cancer", "year": "2016"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:_FxGoFyzp5QC", "citedby": "294"}, {"bib": {"title": "A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies", "year": "2006"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:9yKSN-GCB0IC", "citedby": "265"}, {"bib": {"title": "Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry", "year": "2005"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:2osOgNQ5qMEC", "citedby": "214"}, {"bib": {"title": "Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2 \u2026", "year": "2013"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:IjCSPb-OGe4C", "citedby": "212"}, {"bib": {"title": "Advances in breast cancer: pathways to personalized medicine", "year": "2008"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:UeHWp8X0CEIC", "citedby": "209"}, {"bib": {"title": "BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy", "year": "2005"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:qjMakFHDy7sC", "citedby": "196"}, {"bib": {"title": "Adaptive randomization of neratinib in early breast cancer", "year": "2016"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:Se3iqnhoufwC", "citedby": "182"}, {"bib": {"title": "Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): results from I-SPY 2.", "year": "2017"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:ldfaerwXgEUC", "citedby": "160"}, {"bib": {"title": "A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer", "year": "2014"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:zYLM7Y9cAGgC", "citedby": "153"}, {"bib": {"title": "Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC).", "year": "2015"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:eQOLeE2rZwMC", "citedby": "150"}, {"bib": {"title": "The role of tumor-associated macrophages in breast cancer progression", "year": "2013"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:W7OEmFMy1HYC", "citedby": "145"}, {"bib": {"title": "Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer: Translational Breast Cancer \u2026", "year": "2013"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:YsMSGLbcyi4C", "citedby": "143"}, {"bib": {"title": "Enzalutamide for the treatment of androgen receptor\u2013expressing triple-negative breast cancer", "year": "2018"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:V3AGJWp-ZtQC", "citedby": "117"}, {"bib": {"title": "Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A.", "year": "2017"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:WbkHhVStYXYC", "citedby": "117"}, {"bib": {"title": "Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study", "year": "2019"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:dQ2og3OwTAUC", "citedby": "112"}, {"bib": {"title": "Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study", "year": "2019"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:kzcrU_BdoSEC", "citedby": "105"}, {"bib": {"title": "Estrogen receptor \u03b1, BRCA1, and FANCF promoter methylation occur in distinct subsets of sporadic breast cancers", "year": "2008"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:Y0pCki6q_DkC", "citedby": "93"}, {"bib": {"title": "Atezolizumab in metastatic TNBC (mTNBC): Long-term clinical outcomes and biomarker analyses", "year": "2017"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:sSrBHYA8nusC", "citedby": "89"}, {"bib": {"title": "Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study", "year": "2019"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:tzM49s52ZIMC", "citedby": "77"}, {"bib": {"title": "Phase 2 study of pembrolizumab as first-line therapy for PD-L1\u2013positive metastatic triple-negative breast cancer (mTNBC): preliminary data from KEYNOTE-086 cohort B.", "year": "2017"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:4OULZ7Gr8RgC", "citedby": "72"}, {"bib": {"title": "The neoadjuvant model is still the future for drug development in breast cancer", "year": "2015"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:UebtZRa9Y70C", "citedby": "68"}, {"bib": {"title": "LBA13Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): Results from \u2026", "year": "2017"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:8AbLer7MMksC", "citedby": "67"}, {"bib": {"title": "Phase II trial of temsirolimus in patients with metastatic breast cancer", "year": "2012"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:roLk4NBRz8UC", "citedby": "64"}, {"bib": {"title": "Targeting the human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer: recent advances and future directions", "year": "2007"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:WF5omc3nYNoC", "citedby": "58"}, {"bib": {"title": "Pharmacogenomics\u2010based point\u2010of\u2010care clinical decision support significantly alters drug prescribing", "year": "2017"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:dshw04ExmUIC", "citedby": "54"}, {"bib": {"title": "A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer", "year": "2013"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:ufrVoPGSRksC", "citedby": "53"}, {"bib": {"title": "Significance of circulating tumor cells in metastatic triple-negative breast cancer patients within a randomized, phase II trial: TBCRC 019", "year": "2015"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:8k81kl-MbHgC", "citedby": "50"}, {"bib": {"title": "Monitoring of serum DNA methylation as an early independent marker of response and survival in metastatic breast cancer: TBCRC 005 prospective biomarker study", "year": "2017"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:TFP_iSt0sucC", "citedby": "49"}, {"bib": {"title": "Efficacy of the PARP inhibitor veliparib with carboplatin or as a single agent in patients with germline BRCA1-or BRCA2-associated metastatic breast cancer: California Cancer \u2026", "year": "2017"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:ZHo1McVdvXMC", "citedby": "47"}, {"bib": {"title": "TBCRC 006: A multicenter phase II study of neoadjuvant lapatinib and trastuzumab in patients with HER2-overexpressing breast cancer.", "year": "2011"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:LkGwnXOMwfcC", "citedby": "47"}, {"bib": {"title": "Treatment of leptomeningeal carcinomatosis: current challenges and future opportunities", "year": "2015"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:KlAtU1dfN6UC", "citedby": "44"}, {"bib": {"title": "Neuroblastoma therapy: what is in the pipeline?", "year": "2011"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:PR6Y55bgFSsC", "citedby": "40"}, {"bib": {"title": "TBCRC 019: a phase II trial of nanoparticle albumin-bound paclitaxel with or without the anti-death receptor 5 monoclonal antibody tigatuzumab in patients with triple-negative \u2026", "year": "2015"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:4TOpqqG69KYC", "citedby": "31"}, {"bib": {"title": "Abstract CT227: neratinib plus standard neoadjuvant therapy for high-risk breast cancer: efficacy results from the I-SPY 2 TRIAL", "year": "2014"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:hqOjcs7Dif8C", "citedby": "31"}, {"bib": {"title": "TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases", "year": "2014"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:ULOm3_A8WrAC", "citedby": "30"}, {"bib": {"title": "Abstract S6-02: TBCRC023: A randomized multicenter phase II neoadjuvant trial of lapatinib plus trastuzumab, with endcorine therapy and without chemotherapy, for 12 vs. 24 \u2026", "year": "2015"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:3fE2CSJIrl8C", "citedby": "29"}, {"bib": {"title": "Abstract PD6-10: KEYNOTE-086 cohort B: Pembrolizumab monotherapy for PD-L1\u2013positive, previously untreated, metastatic triple-negative breast cancer (mTNBC)", "year": "2018"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:5ugPr518TE4C", "citedby": "28"}, {"bib": {"title": "Adaptively randomized trial of neoadjuvant chemotherapy with or without the Akt inhibitor MK-2206: Graduation results from the I-SPY 2 Trial", "year": "2015"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:qxL8FJ1GzNcC", "citedby": "28"}, {"bib": {"title": "Phase II study of lapatinib in combination with trastuzumab in patients with human epidermal growth factor receptor 2\u2013positive metastatic breast cancer: clinical outcomes and \u2026", "year": "2015"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:Zph67rFs4hoC", "citedby": "27"}, {"bib": {"title": "Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing \u2026", "year": "2018"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:VOx2b1Wkg3QC", "citedby": "26"}, {"bib": {"title": "\u201cTargeting\u201d triple-negative breast cancer: the lessons learned from BRCA1-associated breast cancers", "year": "2011"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:0EnyYjriUFMC", "citedby": "26"}, {"bib": {"title": "\u201cIntrinsic Gene Expression\u201d subtypes correlated with grade and morphometric parameters reveal a high proportion of aggressive basal-like tumors among black women of African \u2026", "year": "2004"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:MXK_kJrjxJIC", "citedby": "24"}, {"bib": {"title": "Concepts and targets in triple-negative breast cancer: recent results and clinical implications", "year": "2016"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:IWHjjKOFINEC", "citedby": "22"}, {"bib": {"title": "Efficacy of the combination of ABT-888 (veliparib) and carboplatin in patients with BRCA-associated breast cancer.", "year": "2013"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:kNdYIx-mwKoC", "citedby": "22"}, {"bib": {"title": "PIK3CA mutations and/or low PTEN predict resistance to combined anti-HER2 therapy with lapatinib and trastuzumab and without chemotherapy in TBCRC006, a neoadjuvant trial of \u2026", "year": "2013"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:k8Z6L05lTy4C", "citedby": "19"}, {"bib": {"title": "Pathological complete response predicts event-free and distant disease-free survival in the I-SPY2 TRIAL", "year": "2017"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:XiVPGOgt02cC", "citedby": "18"}, {"bib": {"title": "Patient perceptions of care as influenced by a large institutional pharmacogenomic implementation program", "year": "2017"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:RHpTSmoSYBkC", "citedby": "17"}, {"bib": {"title": "Immune checkpoint blockade for breast cancer", "year": "2018"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:mvPsJ3kp5DgC", "citedby": "16"}, {"bib": {"title": "TBCRC-010: phase I/II study of dasatinib in combination with zoledronic acid for the treatment of breast cancer bone metastasis", "year": "2016"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:3s1wT3WcHBgC", "citedby": "16"}, {"bib": {"title": "Phase II trial of single agent PARP inhibitor ABT-888 (veliparib [vel]) followed by postprogression therapy of vel with carboplatin (carb) in patients (pts) with stage BRCA \u2026", "year": "2014"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:M3ejUd6NZC8C", "citedby": "16"}, {"bib": {"title": "Efficacy of T-DM1+ pertuzumab over standard therapy for HER2+ breast cancer: results from the neoadjuvant I-SPY 2 TRIAL", "year": "2016"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:L8Ckcad2t8MC", "citedby": "15"}, {"bib": {"title": "Abstract P2-18-09: TBCRC 013: a prospective analysis of the role of surgery in stage IV breast cancer", "year": "2013"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:mVmsd5A6BfQC", "citedby": "15"}, {"bib": {"title": "Adaptive trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug development", "year": "2012"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:YOwf2qJgpHMC", "citedby": "15"}, {"bib": {"title": "ABT-888 (veliparib) in combination with carboplatin in patients with stage IV BRCA-associated breast cancer. A California Cancer Consortium Trial.", "year": "2012"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:_kc_bZDykSQC", "citedby": "14"}, {"bib": {"title": "LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases", "year": "2018"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:ZuybSZzF8UAC", "citedby": "13"}, {"bib": {"title": "A randomized phase I trial of nanoparticle albumin-bound paclitaxel with or without mifepristone for advanced breast cancer", "year": "2016"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:4JMBOYKVnBMC", "citedby": "13"}, {"bib": {"title": "A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer", "year": "2019"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:epqYDVWIO7EC", "citedby": "12"}, {"bib": {"title": "The M2/Alternatively Activated Macrophage Phenotype Correlates with Aggressive Histopathologic Features and Poor Clinical Outcome in Early Stage Breast Cancer.", "year": "2009"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:Wp0gIr-vW9MC", "citedby": "12"}, {"bib": {"title": "Surgical patterns of care in patients with invasive breast cancer treated with neoadjuvant systemic therapy and breast magnetic resonance imaging: results of a secondary \u2026", "year": "2015"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:9ZlFYXVOiuMC", "citedby": "11"}, {"bib": {"title": "A phase Ib multicohort study of MK-3475 in patients with advanced solid tumors.", "year": "2014"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:R3hNpaxXUhUC", "citedby": "11"}, {"bib": {"title": "Abstract P6-10-03: KEYNOTE-012: Long-lasting responses in a phase Ib study of pembrolizumab for metastatic triple-negative breast cancer (mTNBC)", "year": "2017"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:vV6vV6tmYwMC", "citedby": "10"}, {"bib": {"title": "Analyzing the clinical actionability of germline pharmacogenomic findings in oncology", "year": "2018"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:JoZmwDi-zQgC", "citedby": "9"}, {"bib": {"title": "First international TNBC conference meeting report", "year": "2018"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:1qzjygNMrQYC", "citedby": "9"}, {"bib": {"title": "Abstract PD3-14: Phase 1 study of the antibody-drug conjugate SGN-LIV1A in patients with heavily pretreated triple-negative metastatic breast cancer", "year": "2018"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:bnK-pcrLprsC", "citedby": "9"}, {"bib": {"title": "Overall survival (OS) in patients (Pts) with diagnostic positive (Dx+) breast cancer: Subgroup analysis from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR \u2026", "year": "2017"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:2P1L_qKh6hAC", "citedby": "9"}, {"bib": {"title": "Pembrolizumab for metastatic triple-negative breast cancer (mTNBC): long-lasting responses in the phase Ib KEYNOTE-012 study", "year": "2017"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:u_35RYKgDlwC", "citedby": "9"}, {"bib": {"title": "Abstract P5-19-09: preliminary results from a phase 2 single-arm study of enzalutamide, an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC)", "year": "2015"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:mB3voiENLucC", "citedby": "9"}, {"bib": {"title": "Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: An analysis of the ongoing phase 2 adaptively \u2026", "year": "2020"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:WZBGuue-350C", "citedby": "8"}, {"bib": {"title": "Efficacy of the PARP inhibitor (PI) ABT-888 (veliparib [vel]) either with carboplatin (carb) or as a single agent followed by post-progression therapy in combination with carb \u2026", "year": "2015"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:iH-uZ7U-co4C", "citedby": "8"}, {"bib": {"title": "KEYNOTE-012: A phase Ib study of pembrolizumab (MK-3475) in patients (pts) with metastatic triple-negative breast cancer (mTNBC)", "year": "2015"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:aqlVkmm33-oC", "citedby": "8"}, {"bib": {"title": "TBCRC 003: Phase II trial of trastuzumab (T) and lapatinib (L) in patients (pts) with HER2+ metastatic breast cancer (MBC).", "year": "2010"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:4DMP91E08xMC", "citedby": "8"}, {"bib": {"title": "Immune checkpoint inhibitor therapy in breast cancer", "year": "2018"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:JQOojiI6XY0C", "citedby": "7"}, {"bib": {"title": "Surgical standards for management of the axilla in breast cancer clinical trials with pathological complete response endpoint", "year": "2018"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:1yQoGdGgb4wC", "citedby": "7"}, {"bib": {"title": "TBCRC 019: phase II trial of nab-PAC with/without the anti-death receptor 5 monoclonal antibody tigatuzumab in patients with triple negative breast cancer", "year": "2015"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:-f6ydRqryjwC", "citedby": "6"}, {"bib": {"title": "Whole-exome sequencing (WES) of HER2+ metastatic breast cancer (MBC) from patients (pts) treated with prior trastuzumab (T): A correlative analysis of TBCRC003.", "year": "2014"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:TQgYirikUcIC", "citedby": "6"}, {"bib": {"title": "TBCRC 019: An open-label, randomized, phase II trial of nanoparticle albumin-bound paclitaxel with or without the anti-death receptor 5 (DR5) monoclonal antibody tigatuzumab in \u2026", "year": "2011"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:QIV2ME_5wuYC", "citedby": "6"}, {"bib": {"title": "TBCRC 032 IB/II multicenter study: molecular insights to AR antagonist and PI3K inhibitor efficacy in patients with AR+ metastatic triple-negative breast cancer", "year": "2020"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:lmc2jWPfTJgC", "citedby": "5"}, {"bib": {"title": "Patient-provider communications about pharmacogenomic results increase patient recall of medication changes", "year": "2019"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:_Re3VWB3Y0AC", "citedby": "5"}, {"bib": {"title": "If we build it they will come: targeting the immune response to breast cancer", "year": "2019"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:b1wdh0AR-JQC", "citedby": "5"}, {"bib": {"title": "METRIC: A randomized international phase 2b study of the antibody-drug conjugate (ADC) glembatumumab vedotin (GV) in gpNMB-overexpressing, metastatic, triple-negative breast \u2026", "year": "2019"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:L7CI7m0gUJcC", "citedby": "5"}, {"bib": {"title": "Assessment of provider-perceived barriers to clinical use of pharmacogenomics during participation in an institutional implementation study", "year": "2019"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:tKAzc9rXhukC", "citedby": "5"}, {"bib": {"title": "Perspectives in immunotherapy: meeting report from the \u201cImmunotherapy Bridge\u201d, Napoli, November 30th 2016", "year": "2017"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:fQNAKQ3IYiAC", "citedby": "5"}, {"bib": {"title": "Abstract P6-11-03: A phase 2 open-label study of lucitanib in patients (pts) with FGF aberrant metastatic breast cancer (MBC)", "year": "2017"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:pqnbT2bcN3wC", "citedby": "5"}, {"bib": {"title": "Efficacy of pertuzumab/trastuzumab/paclitaxel over standard trastuzumab/paclitaxel therapy for HER2+ breast cancer: results from the neoadjuvant I-SPY 2 TRIAL", "year": "2016"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:VLnqNzywnoUC", "citedby": "5"}, {"bib": {"title": "Gene expression of peripheral blood cells reveals pathways downstream of glucocorticoid receptor antagonism and nab-paclitaxel treatment", "year": "2014"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:JV2RwH3_ST0C", "citedby": "5"}, {"bib": {"title": "A phase II trial of a mammalian target of rapamycin inhibitor, temsirolimus, in patients with metastatic breast cancer.", "year": "2009"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:dhFuZR0502QC", "citedby": "5"}, {"bib": {"title": "TBCRC023: a randomized phase II neoadjuvant trial of lapatinib plus trastuzumab without chemotherapy for 12 versus 24 weeks in patients with HER2-positive breast cancer", "year": "2020"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:tuHXwOkdijsC", "citedby": "4"}, {"bib": {"title": "LCCC 1025: Phase II study of everolimus, trastuzumab, and vinorelbine for HER2+ breast cancer brain metastases (BCBM).", "year": "2017"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:RGFaLdJalmkC", "citedby": "4"}, {"bib": {"title": "A randomized, phase 2 trial of preoperative MM-121 with paclitaxel in triple negative (TN) and hormone receptor (HR) positive, HER2-negative breast cancer", "year": "2015"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:rO6llkc54NcC", "citedby": "4"}, {"bib": {"title": "A randomized phase I trial of nanoparticle albumin bound paclitaxel (nab-paclitaxel, Abraxane (R)) with or without mifepristone for advanced breast cancer", "year": "2013"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:4fKUyHm3Qg0C", "citedby": "4"}, {"bib": {"title": "Abstract P2-16-05: Efficacy of ABT-888 (veliparib) in patients with BRCA-associated breast cancer", "year": "2013"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:j3f4tGmQtD8C", "citedby": "4"}, {"bib": {"title": "Abstract P2-16-21: A randomized phase I trial of nanoparticle albumin bound paclitaxel (nab-paclitaxel, Abraxane\u00ae) with or without mifepristone for advanced breast cancer", "year": "2013"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:qUcmZB5y_30C", "citedby": "4"}, {"bib": {"title": "TBCRC 018: Phase II study of iniparib plus chemotherapy to treat triple-negative breast cancer (TNBC) central nervous system (CNS) metastases (mets).", "year": "2013"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:HDshCWvjkbEC", "citedby": "4"}, {"bib": {"title": "The role of EGFR amplification in trastuzumab resistance: A correlative analysis of TBCRC003.", "year": "2011"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:e5wmG9Sq2KIC", "citedby": "4"}, {"bib": {"title": "TBCRC 018: Phase II study of iniparib plus chemotherapy to treat triple-negative breast cancer (TNBC) brain metastases (BM).", "year": "2011"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:ZeXyd9-uunAC", "citedby": "4"}, {"bib": {"title": "Molecular classification of west African breast tumors demonstrates an overrepresentation of hormone receptor negative breast cancer", "year": "2007"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:r0BpntZqJG4C", "citedby": "4"}, {"bib": {"title": "Breast tumor morphometry in relation to race reveals significant differences among Nigerians, African-Americans and Caucasian Americans", "year": "2004"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:7PzlFSSx8tAC", "citedby": "4"}, {"bib": {"title": "Abstract CT042: Efficacy of T-DM1+ pertuzumab over standard therapy for HER2+ breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL", "year": "2016"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:BqipwSGYUEgC", "citedby": "3"}, {"bib": {"title": "Utility of patient-derived lymphoblastoid cell lines as an ex vivo capecitabine sensitivity prediction model for breast cancer patients", "year": "2016"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:blknAaTinKkC", "citedby": "3"}, {"bib": {"title": "Early and severe radiation esophagitis associated with concurrent sirolimus", "year": "2016"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:_Qo2XoVZTnwC", "citedby": "3"}, {"bib": {"title": "A phase 2, randomized, open-label study of lucitanib in patients with FGF aberrant metastatic breast cancer.", "year": "2015"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:HoB7MX3m0LUC", "citedby": "3"}, {"bib": {"title": "Relationship between BRCA1 promoter methylation and sensitivity of breast cancer cell lines to cisplatin and paclitaxel", "year": "2007"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:hC7cP41nSMkC", "citedby": "3"}, {"bib": {"title": "A New Breast Tumor Intrinsic Gene List Identifies Novel Characteristics that are Conserved Across Microarray Platforms", "year": "2006"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:ns9cj8rnVeAC", "citedby": "3"}, {"bib": {"title": "Computerized analysis of carotid plaque density", "year": "1996"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:eflP2zaiRacC", "citedby": "3"}, {"bib": {"title": "Abstract P6-02-01: The effect of background parenchymal enhancement on the predictive performance of functional tumor volume measured in MRI", "year": "2020"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:PoWvk5oyLR8C", "citedby": "2"}, {"bib": {"title": "Abstract GS1-05: TBCRC 033: A randomized phase II study of adjuvant trastuzumab emtansine (T-DM1) vs paclitaxel (T) in combination with trastuzumab (H) for stage I HER2 \u2026", "year": "2020"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:oNZyr7d5Mn4C", "citedby": "2"}, {"bib": {"title": "Analysis of immune cell infiltrates as predictors of response to the checkpoint inhibitor pembrolizumab in the neoadjuvant I-SPY 2 TRIAL", "year": "2019"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:gsN89kCJA0AC", "citedby": "2"}, {"bib": {"title": "Quantitative MHC II protein expression levels in tumor epithelium to predict response to the PD1 inhibitor pembrolizumab in the I-SPY 2 Trial.", "year": "2019"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:BUYA1_V_uYcC", "citedby": "2"}, {"bib": {"title": "Retrospective chart evaluation of hypercalcemia management in oncology patients at the University of Chicago Medical Center", "year": "2019"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:LPZeul_q3PIC", "citedby": "2"}, {"bib": {"title": "Abstract PD6-08: analysis of immune infiltrates (assessed via multiplex fluorescence immunohistochemistry) and immune gene expression signatures as predictors of response to \u2026", "year": "2018"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:J-pR_7NvFogC", "citedby": "2"}, {"bib": {"title": "Analysis of DNA repair deficiency biomarkers as predictors of response to the PD1 inhibitor pembrolizumab: Results from the neoadjuvant I-SPY 2 trial for stage II-III high-risk \u2026", "year": "2018"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:WA5NYHcadZ8C", "citedby": "2"}, {"bib": {"title": "Impact of tissue-based genomic profiling on clinical decision making in the management of patients with metastatic breast cancer at academic centers", "year": "2017"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:geHnlv5EZngC", "citedby": "2"}, {"bib": {"title": "Abstract P6-11-04: The evaluation of ganitumab/metformin plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial", "year": "2017"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:NaGl4SEjCO4C", "citedby": "2"}, {"bib": {"title": "Abstract P3-07-25: Improved clinical outcomes on enzalutamide observed in patients with PREDICT AR+ triple-negative breast cancer: prognosis or prediction?", "year": "2016"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:UxriW0iASnsC", "citedby": "2"}, {"bib": {"title": "Abstract PD3-5: Whole exome sequencing (WES) of HER2+ metastatic breast cancer (MBC) from patients with or without prior trastuzumab (T): A correlative analysis of TBCRC003", "year": "2015"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:O3NaXMp0MMsC", "citedby": "2"}, {"bib": {"title": "Abstract PD1-2: PIK3CA mutations and/or low PTEN predict resistance to combined anti-HER2 therapy with lapatinib and trastuzumab and without chemotherapy in TBCRC006, a \u2026", "year": "2013"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:5nxA0vEk-isC", "citedby": "2"}, {"bib": {"title": "A phase I trial of the IGF-1R antibody IMC-A12 in combination with temsirolimus in patients with metastatic breast cancer.", "year": "2012"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:l7t_Zn2s7bgC", "citedby": "2"}, {"bib": {"title": "Circulating tumor cell (CTC) and CA2729 as predictors of outcome in patients with metastatic breast cancer (MBC) in the prospective TBCRC 005 biomarker study.", "year": "2010"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:hFOr9nPyWt4C", "citedby": "2"}, {"bib": {"title": "Characterization of aggressive breast cancer in African American and Caucasian women: patterns of gene expression in primary breast tumors", "year": "2004"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:bEWYMUwI8FkC", "citedby": "2"}, {"bib": {"title": "Annual Conference"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:UHK10RUVsp4C", "citedby": "2"}, {"bib": {"title": "Atezolizumab for the treatment of breast cancer", "year": "2020"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:XoXfffV-tXoC", "citedby": "1"}, {"bib": {"title": "Abstract GS5-02: Detection of circulating tumor DNA (ctDNA) after neoadjuvant chemotherapy is significantly associated with disease recurrence in early-stage triple-negative \u2026", "year": "2020"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:Dip1O2bNi0gC", "citedby": "1"}, {"bib": {"title": "Abstract GS3-08: Multiplatform analysis of matched primary and metastatic breast tumors from the AURORA US Network", "year": "2020"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:SpbeaW3--B0C", "citedby": "1"}, {"bib": {"title": "RNA molecular signatures as predictive biomarkers of response to monotherapy pembrolizumab in patients with metastatic triple-negative breast cancer: KEYNOTE-086", "year": "2019"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:TIZ-Mc8IlK0C", "citedby": "1"}, {"bib": {"title": "Integration of DNA repair deficiency and immune biomarkers to predict which early-stage triple-negative breast cancer patients are likely to respond to platinum-containing \u2026", "year": "2019"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:BwyfMAYsbu0C", "citedby": "1"}, {"bib": {"title": "Abstract PD2-12: Palbociclib in combination with fulvestrant or tamoxifen as treatment for hormone receptor positive (HR+) metastatic breast cancer (MBC) with prior \u2026", "year": "2019"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:ipzZ9siozwsC", "citedby": "1"}, {"bib": {"title": "363TiP Phase Ib/IIa study of RX-5902, a novel orally bioavailable inhibitor of phosphorylated P68, which prevents nuclear \u03b2-catenin translocation in patients with triple \u2026", "year": "2018"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:_Ybze24A_UAC", "citedby": "1"}, {"bib": {"title": "Abstract PD6-14: Analysis of DNA repair deficiency biomarkers as predictors of response to the PD1 inhibitor pembrolizumab: Results from the neoadjuvant I-SPY 2 trial for stage \u2026", "year": "2018"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:wbdj-CoPYUoC", "citedby": "1"}, {"bib": {"title": "Analysis of immune infiltrates (assessed via multiplex fluorescence immunohistochemistry) and immune gene expression signatures as predictors of response to the checkpoint \u2026", "year": "2018"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:HE397vMXCloC", "citedby": "1"}, {"bib": {"title": "A phase I trial of mifepristone (M), carboplatin (C), and gemcitabine (G) in advanced breast and ovarian cancer.", "year": "2017"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:738O_yMBCRsC", "citedby": "1"}, {"bib": {"title": "Abstract CT106: Efficacy of pertuzumab/trastuzumab/paclitaxel over standard trastuzumab/paclitaxel therapy for HER2+ breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL", "year": "2016"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:tOudhMTPpwUC", "citedby": "1"}, {"bib": {"title": "Abstract OT1-03-15: the METRIC trial: a randomized international study of the antibody-drug conjugate glembatumumab vedotin (GV or CDX-011) in patients with metastatic gpNMB \u2026", "year": "2016"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:abG-DnoFyZgC", "citedby": "1"}, {"bib": {"title": "Cytotoxic CD8+ T cells and immunosuppressive T regulatory cells are associated with aggressive breast cancer subtypes", "year": "2015"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:CHSYGLWDkRkC", "citedby": "1"}, {"bib": {"title": "Mifepristone (MIFE), a glucocorticoid receptor (GR) antagonist, in combination with eribulin (E) in advanced solid tumors: A phase 1 study with dose expansion in patients (pts \u2026", "year": "2015"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:nb7KW1ujOQ8C", "citedby": "1"}, {"bib": {"title": "TBCRC-010: Phase I/II study of dasatinib in combination with zoledronic acid (ZA) for the treatment of breast cancer bone metastasis (MBC-bone).", "year": "2015"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:lSLTfruPkqcC", "citedby": "1"}, {"bib": {"title": "Abstract P3-11-03: A randomized, phase 2 trial of preoperative MM-121 with paclitaxel in triple negative (TN) and hormone receptor (HR) positive, HER2-negative breast cancer", "year": "2015"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:70eg2SAEIzsC", "citedby": "1"}, {"bib": {"title": "Nodal patterns of care in patients with invasive breast cancer treated with neoadjuvant systemic therapy: Results of a secondary analysis of TBCRC 017", "year": "2013"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:t7zJ5fGR-2UC", "citedby": "1"}, {"bib": {"title": "TBCRC 002: A phase II, randomized, open label trial of preoperative letrozole versus letrozole (LET) in combination with bevacizumab (BEV) in post-menopausal women with newly \u2026", "year": "2013"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:NMxIlDl6LWMC", "citedby": "1"}, {"bib": {"title": "TBCRC 019: An open label, randomized, phase II trial of nanoparticle albumin-bound paclitaxel (nab-PAC) with or without the anti-death receptor 5 (DR5) monoclonal antibody \u2026", "year": "2013"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:hMod-77fHWUC", "citedby": "1"}, {"bib": {"title": "Stage 1 results from a 2-stage study of enzalutamide, an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC)", "year": "2011"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:k_IJM867U9cC", "citedby": "1"}, {"bib": {"title": "Outcomes after breast cancer in an ethnically diverse cohort of high-risk patients: Differences in survival based on BRCA1/BRCA2 mutation status", "year": "2007"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:GnPB-g6toBAC", "citedby": "1"}, {"bib": {"title": "The role of BRCA1 promoter methylation in determining chemosensitivity in vitro", "year": "2006"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:M3NEmzRMIkIC", "citedby": "1"}, {"bib": {"title": "The importance of the Doppler angle.", "year": "1997"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:BrmTIyaxlBUC", "citedby": "1"}, {"bib": {"title": "TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone \u2026", "year": "2020"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:foquWX3nUaYC", "citedby": "0"}, {"bib": {"title": "Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015.", "year": "2020"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:Ug5p-4gJ2f0C", "citedby": "0"}, {"bib": {"title": "MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2\u2013Positive and/or Hormone Receptor\u2013Negative Breast \u2026", "year": "2020"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:kz9GbA2Ns4gC", "citedby": "0"}, {"bib": {"title": "Abstract PD9-05: Lack of background parenchymal enhancement suppression in breast MRI during neoadjuvant chemotherapy may be associated with inferior treatment response in \u2026", "year": "2020"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:ruyezt5ZtCIC", "citedby": "0"}, {"bib": {"title": "Abstract P2-20-02: Site of recurrence after neoadjuvant therapy: Clues to biology and impact on endpoints", "year": "2020"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:q3CdL3IzO_QC", "citedby": "0"}, {"bib": {"title": "Abstract OT2-04-05: Pembrolizumab in combination with carboplatin versus carboplatin alone in breast cancer patients with chest wall disease: Translational Breast Cancer \u2026", "year": "2020"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:HbR8gkJAVGIC", "citedby": "0"}, {"bib": {"title": "Abstract PD9-04: Breast cancer subtype specific association of pCR with MRI assessed tumor volume progression during NAC in the I-SPY 2 trial", "year": "2020"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:xtoqd-5pKcoC", "citedby": "0"}, {"bib": {"title": "Abstract OT1-08-03: Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of adagloxad simolenin (OBI-822) and OBI-821 treatment in \u2026", "year": "2020"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:i2xiXl-TujoC", "citedby": "0"}, {"bib": {"title": "Abstract PD10-02: Patient reported outcomes from the adjuvant trastuzumab emtansine (T-DM1) vs. paclitaxel+ trastuzumab (TH)(ATEMPT) trial (TBCRC 033)", "year": "2020"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:S16KYo8Pm5AC", "citedby": "0"}, {"bib": {"title": "Abstract P2-13-02: Chemotherapy-related amenorrhea (CRA) after adjuvant trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH)(TBCRC033 \u2026", "year": "2020"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:e_rmSamDkqQC", "citedby": "0"}, {"bib": {"title": "Abstract P3-09-02: Evaluation of a novel agent plus standard neoadjuvant therapy in early stage, high-risk HER2 negative breast cancer: Results from the I-SPY 2 TRIAL", "year": "2020"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:-FonjvnnhkoC", "citedby": "0"}, {"bib": {"title": "Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer", "year": "2019"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:KUbvn5osdkgC", "citedby": "0"}, {"bib": {"title": "Evaluation of talazoparib in combination with irinotecan in early stage, high-risk HER2 negative breast cancer: Results from the I-SPY 2 TRIAL", "year": "2019"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:tYavs44e6CUC", "citedby": "0"}, {"bib": {"title": "Palbociclib in combination with fulvestrant or tamoxifen as treatment for hormone receptor positive metastatic breast cancer with prior chemotherapy for advanced disease (TBCRC \u2026", "year": "2019"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:hMsQuOkrut0C", "citedby": "0"}, {"bib": {"title": "Abstract CT003: Analysis of immune cell infiltrates as predictors of response to the checkpoint inhibitor pembrolizumab in the neoadjuvant I-SPY 2 TRIAL", "year": "2019"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:EYYDruWGBe4C", "citedby": "0"}, {"bib": {"title": "Abstract LB-225: RNA molecular signatures as predictive biomarkers of response to monotherapy pembrolizumab in patients with metastatic triple-negative breast cancer: KEYNOTE-086", "year": "2019"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:vbGhcppDl1QC", "citedby": "0"}, {"bib": {"title": "Abstract CT128: Palbociclib in combination with fulvestrant or tamoxifen as treatment for hormone receptor positive metastatic breast cancer with prior chemotherapy for \u2026", "year": "2019"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:4MWp96NkSFoC", "citedby": "0"}, {"bib": {"title": "Triple-negative breast cancer cell-intrinsic glucocorticoid receptor activity and modulation of the immune microenvironment", "year": "2019"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:ML0RJ9NH7IQC", "citedby": "0"}, {"bib": {"title": "Abstract CT136: Evaluation of talazoparib in combination with irinotecan in early stage, high-risk HER2 negative breast cancer: Results from the I-SPY 2 TRIAL", "year": "2019"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:Z5m8FVwuT1cC", "citedby": "0"}, {"bib": {"title": "Characterizing the gut microbiome of patients with triple-negative breast cancer.", "year": "2019"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:AvfA0Oy_GE0C", "citedby": "0"}, {"bib": {"title": "Abstract P2-14-01: The impact of local therapy on locoregional recurrence in women with high risk breast cancer in the neoadjuvant I-SPY2 TRIAL", "year": "2019"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:EkHepimYqZsC", "citedby": "0"}, {"bib": {"title": "Abstract P1-15-02: Withdrawn", "year": "2019"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:uc_IGeMz5qoC", "citedby": "0"}, {"bib": {"title": "Abstract OT3-04-04: A randomized phase II study of pembrolizumab in combination with carboplatin versus carboplatin alone in breast cancer patients with chest wall disease \u2026", "year": "2019"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:0KyAp5RtaNEC", "citedby": "0"}, {"bib": {"title": "Abstract P2-07-03: Refining neoadjuvant predictors of three year distant metastasis free survival: Integrating volume change as measured by MRI with residual cancer burden", "year": "2019"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:nrtMV_XWKgEC", "citedby": "0"}, {"bib": {"title": "Refining neoadjuvant predictors of three year distant metastasis free survival: Integrating volume change as measured by MRI with residual cancer burden", "year": "2019"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:g3aElNc5_aQC", "citedby": "0"}, {"bib": {"title": "A randomized phase II study of pembrolizumab in combination with carboplatin versus carboplatin alone in breast cancer patients with chest wall disease, with immunologic and \u2026", "year": "2019"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:ILKRHgRFtOwC", "citedby": "0"}, {"bib": {"title": "Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint (vol 4, 26, 2018)", "year": "2019"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:VaXvl8Fpj5cC", "citedby": "0"}, {"bib": {"title": "Erratum: Author Correction: Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint.", "year": "2019"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:ZfRJV9d4-WMC", "citedby": "0"}, {"bib": {"title": "Phase Ib/IIa study of RX-5902, a novel orally bioavailable inhibitor of phosphorylated P68, which prevents nuclear \u03b2-catenin translocation in patients with triple negative \u2026", "year": "2018"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:zLWjf1WUPmwC", "citedby": "0"}, {"bib": {"title": "A randomized phase II study of pembrolizumab, an anti-PD (programmed cell death) 1 antibody, in combination with carboplatin compared to carboplatin alone in breast cancer \u2026", "year": "2018"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:WqliGbK-hY8C", "citedby": "0"}, {"bib": {"title": "Preliminary report of a phase 1b/2a trial, an oral inhibitor of phosphorylated P68 (P-p68) which mediates \u03b2-catenin nuclear translocation in advanced triple-negative breast \u2026", "year": "2018"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:5awf1xo2G04C", "citedby": "0"}, {"bib": {"title": "Clinical evaluation of germline polymorphisms (SNPs) associated with disease response to capecitabine in metastatic breast cancer (MBC)(TBCRC 015).", "year": "2018"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:eq2jaN3J8jMC", "citedby": "0"}, {"bib": {"title": "Abstract OT1-02-03: TBCRC 044: A randomized phase II study of pembrolizumab in combination with carboplatin versus carboplatin alone in breast cancer patients with chest wall \u2026", "year": "2018"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:olpn-zPbct0C", "citedby": "0"}, {"bib": {"title": "TBCRC 044: A randomized phase II study of pembrolizumab in combination with carboplatin versus carboplatin alone in breast cancer patients with chest wall disease", "year": "2018"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:AXPGKjj_ei8C", "citedby": "0"}, {"bib": {"title": "Molecular Profiling and Targeted Therapy for Triple-Negative Breast Cancer", "year": "2018"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:q3oQSFYPqjQC", "citedby": "0"}, {"bib": {"title": "Immunotherapy Approaches to Breast Cancer", "year": "2017"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:5Ul4iDaHHb8C", "citedby": "0"}, {"bib": {"title": "Biomarkers of immune infiltration for multiplex immunofluorescence in breast cancer", "year": "2017"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:B3FOqHPlNUQC", "citedby": "0"}, {"bib": {"title": "Abstract P6-11-02: Efficacy of Hsp90 inhibitor ganetespib plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial", "year": "2017"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:EUQCXRtRnyEC", "citedby": "0"}, {"bib": {"title": "Abstract P6-12-15: Efficacy results of a phase 1/2 study of glucocorticoid receptor (GR) antagonist mifepristone (MIFE) in combination with eribulin in GR-positive triple \u2026", "year": "2017"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:dfsIfKJdRG4C", "citedby": "0"}, {"bib": {"title": "Abstract OT3-04-01: BRE12-158: A phase II randomized controlled trial of genomically directed therapy after preoperative chemotherapy in patients with triple negative breast \u2026", "year": "2017"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:SeFeTyx0c_EC", "citedby": "0"}, {"bib": {"title": "BRE12-158: A phase II randomized controlled trial of genomically directed therapy after preoperative chemotherapy in patients with triple negative breast cancer (TNBC)", "year": "2017"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:uJ-U7cs_P_0C", "citedby": "0"}, {"bib": {"title": "Perspectives in immunotherapy: meeting report from the \u201cImmunotherapy Bridge\u201d, Napoli, December 5 th 2015", "year": "2016"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:_xSYboBqXhAC", "citedby": "0"}, {"bib": {"title": "Retrospective chart evaluation of the efficacy of hypercalcemia of management in oncology patients at the University of Chicago Medical Center.: 137.", "year": "2016"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:P5F9QuxV20EC", "citedby": "0"}, {"bib": {"title": "Phase 1/2 study of glucocorticoid receptor (GR) antagonist mifepristone (MIFE) in combination with eribulin (E) in advanced solid tumors, with dose expansion in patients with \u2026", "year": "2016"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:08ZZubdj9fEC", "citedby": "0"}, {"bib": {"title": "Suppression of poly-ADP ribose (PAR) levels in PBMCs by veliparib (vel) as a pharmacodynamic (PD) marker associated with survival among women with BRCA1-or BRCA2-(BRCA \u2026", "year": "2016"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:XiSMed-E-HIC", "citedby": "0"}, {"bib": {"title": "Factors Associated With the Decision to Pursue Elective Surgery Among Women Enrolled in TBCRC013: A Prospective Registry of Surgery in Patients Presenting With Stage IV Breast \u2026", "year": "2016"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:KxtntwgDAa4C", "citedby": "0"}, {"bib": {"title": "Improved clinical outcomes on enzalutamide observed in patients with PREDICT AR plus triple-negative breast cancer: prognosis or prediction?", "year": "2016"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:9Nmd_mFXekcC", "citedby": "0"}, {"bib": {"title": "Phase 1 study of GR antagonist mifepristone in combination with eribulin in advanced solid tumors, with dose expansion in patients with GR-positive triple-negative breast \u2026", "year": "2016"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:XD-gHx7UXLsC", "citedby": "0"}, {"bib": {"title": "The role of glucocorticoid receptor (GR) expression in predicting pathological complete response (pCR) to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC)", "year": "2016"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:z_wVstp3MssC", "citedby": "0"}, {"bib": {"title": "The METRIC trial: A randomized international study of the antibody-drug conjugate glembatumumab vedotin (GV or CDX-011) in patients with metastatic gpNMB-overexpressing triple \u2026", "year": "2016"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:j8SEvjWlNXcC", "citedby": "0"}, {"bib": {"title": "Treatment outcomes in patients with invasive breast cancer treated with neoadjuvant systemic therapy and breast MR imaging: Results of a secondary analysis of TBCRC 017", "year": "2016"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:evX43VCCuoAC", "citedby": "0"}, {"bib": {"title": "Abstract S3-06: Treatment outcomes in patients with invasive breast cancer treated with neoadjuvant systemic therapy and breast MR imaging: Results of a secondary analysis of \u2026", "year": "2016"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:tS2w5q8j5-wC", "citedby": "0"}, {"bib": {"title": "Abstract P6-13-21: Phase 1 study of GR antagonist mifepristone (M) in combination with eribulin (E) in advanced solid tumors, with dose expansion in patients (pts) with GR \u2026", "year": "2016"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:vRqMK49ujn8C", "citedby": "0"}, {"bib": {"title": "Abstract P3-07-24: The role of glucocorticoid receptor (GR) expression in predicting pathological complete response (pCR) to neoadjuvant chemotherapy in triple-negative breast \u2026", "year": "2016"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:u9iWguZQMMsC", "citedby": "0"}, {"bib": {"title": "Adaptive Randomization of Veliparib\u2013Carboplatin Treatment in Breast Cancer", "year": "2016"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:MLfJN-KU85MC", "citedby": "0"}, {"bib": {"title": "TBCRC 019: An open label, randomized, phase II trial of nanoparticle albumin-bound paclitaxel (nab-PAC or Abraxane\u00ae) with or without the anti-death receptor 5 (DR5) monoclonal \u2026", "year": "2015"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:uLbwQdceFCQC", "citedby": "0"}, {"bib": {"title": "Clinical evaluation of germline polymorphisms (SNPs) associated with capecitabine (C) toxicity (tox) in metastatic breast cancer (MBC).", "year": "2015"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:xtRiw3GOFMkC", "citedby": "0"}, {"bib": {"title": "DNA methylation in serum as an independent marker of outcome and treatment response in TBCRC 005: A prospective study in metastatic breast cancer (MBC) patients.", "year": "2015"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:D03iK_w7-QYC", "citedby": "0"}, {"bib": {"title": "MammaPrint High1/High2 risk class as a biomarker of response to neratinib plus standard neoadjuvant therapy for breast cancer in the I-SPY 2 TRIAL", "year": "2015"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:K3LRdlH-MEoC", "citedby": "0"}, {"bib": {"title": "Abstract P3-06-29: MammaPrint High1/High2 risk class as a biomarker of response to neratinib plus standard neoadjuvant therapy for breast cancer in the I-SPY 2 TRIAL", "year": "2015"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:fPk4N6BV_jEC", "citedby": "0"}, {"bib": {"title": "Signi fi cance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019", "year": "2015"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:-_dYPAW6P2MC", "citedby": "0"}, {"bib": {"title": "Takeaways from the San Antonio Breast Cancer Symposium", "year": "2014"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:isC4tDSrTZIC", "citedby": "0"}, {"bib": {"title": "Significance of circulating tumor cells in metastatic triple negative breast cancer: Results of an open label, randomized, phase II trial of nanoparticle albumin-bound \u2026", "year": "2013"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:fEOibwPWpKIC", "citedby": "0"}, {"bib": {"title": "Abstract P5-01-04: Activation of toll-like receptor 7 (TLR7) confers protection in human breast cancer", "year": "2013"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:a0OBvERweLwC", "citedby": "0"}, {"bib": {"title": "Abstract P1-04-01: Significance of circulating tumor cells in metastatic triple negative breast cancer: Results of an open label, randomized, phase II trial of nanoparticle \u2026", "year": "2013"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:RYcK_YlVTxYC", "citedby": "0"}, {"bib": {"title": "Abstract P1-01-04: Nodal patterns of care in patients with invasive breast cancer treated with neoadjuvant systemic therapy: Results of a secondary analysis of TBCRC 017", "year": "2013"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:maZDTaKrznsC", "citedby": "0"}, {"bib": {"title": "DNA Synthesis and Repair", "year": "2013"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:bFI3QPDXJZMC", "citedby": "0"}, {"bib": {"title": "Association of downregulation of toll-like receptor 3 (TLR3) expression with aggressive breast cancer (BC).", "year": "2013"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:SP6oXDckpogC", "citedby": "0"}, {"bib": {"title": "Dose-ranging randomized pharmacokinetic (PK) and pharmacodynamic (PD) study of vorinostat in patients with advanced solid tumors.", "year": "2013"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:yD5IFk8b50cC", "citedby": "0"}, {"bib": {"title": "Our Takeaways from the San Antonio Breast Cancer Symposium", "year": "2013"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:pyW8ca7W8N0C", "citedby": "0"}, {"bib": {"title": "P2-09-07: Metabolic Response by FDG-PET in Patients (pts) Receiving Trastuzumab (T) and Lapatinib (L) for HER2+ Metastatic Breast Cancer (MBC): Correlative Analysis of TBCRC 003.", "year": "2011"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:p2g8aNsByqUC", "citedby": "0"}, {"bib": {"title": "P2-15-01: Surgical Patterns of Care after Magnetic Resonance Imaging in the Academic Setting in Patients with Operable Breast Cancer Treated with Neoadjuvant Systemic Therapy \u2026", "year": "2011"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:NhqRSupF_l8C", "citedby": "0"}, {"bib": {"title": "Adjuvant chemotherapy in American and Italian patients with BRCA1/2-associated breast cancer.", "year": "2011"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:b0M2c_1WBrUC", "citedby": "0"}, {"bib": {"title": "T regulatory cells are associated with the M2/alternatively activated macrophage phenotype and the basal-like breast cancer subtype", "year": "2010"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:f2IySw72cVMC", "citedby": "0"}, {"bib": {"title": "Abstract# 5186: BRCA1 methylation in sporadic breast cancer", "year": "2009"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:M05iB0D1s5AC", "citedby": "0"}, {"bib": {"title": "The role of VEGFR-2 genetic variation in breast cancer progression.", "year": "2009"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:35N4QoGY0k4C", "citedby": "0"}, {"bib": {"title": "PMCID: PMC2849646.", "year": "2008"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:M7yex6snE4oC", "citedby": "0"}, {"bib": {"title": "Breast cancer outcomes in an ethnically diverse clinic-based cohort of high-risk individuals", "year": "2007"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:J_g5lzvAfSwC", "citedby": "0"}, {"bib": {"title": "Estrogen receptor \u03b1 (ER), BRCA1 and FANCF promoter methylation occur in distinct subsets of sporadic breast cancers", "year": "2007"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:Tiz5es2fbqcC", "citedby": "0"}, {"bib": {"title": "The Characterization and Treatment of Aggressive Breast Cancer", "year": "2007"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:uWQEDVKXjbEC", "citedby": "0"}, {"bib": {"title": "BRCA1 promoter methylation confers sensitivity to cisplatin in vitro", "year": "2005"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:OU6Ihb5iCvQC", "citedby": "0"}, {"bib": {"title": "DEPISTAGE GENETIQUE DANS UNE COHORTE ETHNIQUEMENT DIVERSIFIEE DE FEMMES A RISQUE ELEVE: ANALYSE COMPARATIVE DES MUTATIONS BRCA1 ET BRCA2 AU SEIN DE FAMILLES AMERICAINES D \u2026", "year": "2005"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:1sJd4Hv_s6UC", "citedby": "0"}, {"bib": {"title": "Molecular markers in hereditary breast cancer", "year": "1998"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:g5m5HwL7SMYC", "citedby": "0"}, {"bib": {"title": "European Society for Medical Oncology and the Japanese Society of Medical Oncology"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:LI9QrySNdTsC", "citedby": "0"}, {"bib": {"title": "A phase study of atezolizumab in metastatic triple-negative breast cancer: long-term clinical outcomes and biomarker analyses"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:kuK5TVdYjLIC", "citedby": "0"}, {"bib": {"title": "Search Site"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:2KloaMYe4IUC", "citedby": "0"}, {"bib": {"title": "Immune Checkpoint Inhibition for Triple-negative Breast Cancer"}, "source": "citations", "id_citations": "hnyo1AUAAAAJ:Fu2w8maKXqMC", "citedby": "0"}]}